Develops an investigational psilocybin treatment for people with serious mental health conditions, initially treatment-resistant depression, with PTSD also in development.
10-K for FY2025, filed Mar 24, 2026We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by…View ↗
We believe that our COMP360 psilocybin treatment could offer a new approach to treatment of serious mental health conditions, including…View ↗
Based on the data from this trial, we determined to advance development of COMP360 for PTSD and finalized the design of a Phase 2b/3…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 24, 2026
10-Q for Q3 FY2026, filed Nov 3, 2026
−$9.8MView ↗
A narrower development focus
The older report describes an anorexia program and research into additional compounds; the latest report focuses its pipeline on treatment-resistant depression and PTSD.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 24, 2026
Competes with Janssen, Supernus Pharmaceuticals, Neurocrine Biosciences, GH Research, Beckley Psytech, Usona Institute, and Helus Pharma
10-K for FY2025, filed Mar 24, 2026Currently, only two pharmacotherapies are approved for TRD in the U.S.: Spravato (esketamine), marketed by Janssen, which is an NMDA…View ↗
Loading...